{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:44Z","timestamp":1792787864292,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Karolinska Institute","id":[{"id":"https:\/\/ror.org\/056d84691","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n                      remains the leading bacterial cause of community-acquired pneumonia (CAP) and a major source of morbidity and mortality in adults. Pneumococcal conjugate vaccines (PCVs) have substantially reduced invasive pneumococcal disease, but serotype replacement has led to shifts in pneumococcal CAP epidemiology. In addition, the identification of\n                      <jats:italic>S. pneumoniae<\/jats:italic>\n                      remains challenging. This study investigated pneumococcal serotype distribution, vaccine coverage, and the diagnostic yield of a serotype-specific urinary antigen detection assay (ssUAD) among adults with CAP in Switzerland between 2016 and 2021.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients enrolled in the Swiss CAPNETZ cohort with available urine samples were analyzed using the Pfizer 24-serotype ssUAD assay. Results were compared with conventional diagnostic methods, including the pneumococcal urinary antigen test (pUAT) and cultures. Serotype distribution, vaccine coverage (PCV13, PCV15, PCV20 and PCV21), and temporal trends were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 234 CAP patients,\n                      <jats:italic>S. pneumoniae<\/jats:italic>\n                      was identified by conventional diagnostics (pUAT and cultures combined) in 37 (15.8%). The ssUAD was positive in 35 patients (15.0%). Among patients with available results from both conventional diagnostics and ssUAD (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009161), the addition of ssUAD increased pneumococcal CAP detection from 18.6% to 29.2% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.036). Among ssUAD-positive patients, the most frequent serotypes detected by ssUAD were 3 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912), 8 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095), and 11A (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094). Based on ssUAD-derived serotype distribution, vaccine coverage was 54.3% for PCV13, 60.0% for PCV15, 91.4% for PCV20, and 85.7% for PCV21. During 2020\u20132021, the proportion of serotypes not covered by PCV13 increased from 10\/28 (35.7%) to 6\/7 (85.7%) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.018).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The addition of ssUAD improved\n                      <jats:italic>S. pneumoniae<\/jats:italic>\n                      detection beyond standard methods. Although based on a small number of cases, the shift toward non-PCV13 serotypes underscores the potential benefit of higher-valency vaccines such as PCV20 and PCV21 for adult pneumococcal disease prevention in Switzerland.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-14493-y","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:04:42Z","timestamp":1789970682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pneumococcal serotype distribution and diagnostic yield of serotype-specific urinary antigen detection in adults with CAP in Switzerland, 2016\u20132021: a prospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Samuel","family":"Etienne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner C.","family":"Albrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias W.","family":"Pletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Panning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian Suarez","family":"Domenech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grit","family":"Barten-Neiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana","family":"Stolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"14493_CR1","unstructured":"WHO, Global Health E. 2024 [cited 2026 August 3]; Available from: https:\/\/www.who.int\/data\/global-health-estimates"},{"issue":"4","key":"14493_CR2","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1007\/s12325-020-01248-7","volume":"37","author":"J Ferreira-Coimbra","year":"2020","unstructured":"Ferreira-Coimbra J, Sarda C, Rello J. Burden of Community-Acquired Pneumonia and Unmet Clinical Needs. Adv Ther. 2020;37(4):1302\u201318.","journal-title":"Adv Ther"},{"issue":"10","key":"14493_CR3","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/cid\/cix549","volume":"65","author":"DM Musher","year":"2017","unstructured":"Musher DM, Abers MS, Bartlett JG. Evolving Understanding of the Causes of Pneumonia in Adults, With Special Attention to the Role of Pneumococcus. Clin Infect Dis. 2017;65(10):1736\u201344.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 5","key":"14493_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/1469-0691.12461","volume":"20","author":"JJ Drijkoningen","year":"2014","unstructured":"Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20(Suppl 5):45\u201351.","journal-title":"Clin Microbiol Infect"},{"key":"14493_CR5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fmed.2019.00286","volume":"6","author":"WC Albrich","year":"2019","unstructured":"Albrich WC, et al. Influence of Older Age and Other Risk Factors on Pneumonia Hospitalization in Switzerland in the Pneumococcal Vaccine Era. Front Med (Lausanne). 2019;6:286.","journal-title":"Front Med (Lausanne)"},{"key":"14493_CR6","unstructured":"FOPH. Swiss Federal Office of Public Health factsheet. Pneumokokken-Impfung neu f\u00fcr alle Personen ab dem Alter von 65 Jahren als erg\u00e4nzende Impfung empfohlen. 2023; Available from: https:\/\/www.bag.admin.ch\/dam\/de\/sd-web\/qMNCZMz0rbCu\/pneumokokkenimpfung-plus65.pdf"},{"issue":"7","key":"14493_CR7","doi-asserted-by":"publisher","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","volume":"6","author":"B Wahl","year":"2018","unstructured":"Wahl B, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 2018;6(7):e744\u201357.","journal-title":"Lancet Glob Health"},{"key":"14493_CR8","doi-asserted-by":"crossref","unstructured":"Ladhani SN, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441\u201351.","DOI":"10.1016\/S1473-3099(18)30052-5"},{"key":"14493_CR9","doi-asserted-by":"crossref","unstructured":"Oyewole OR et al. The Impact of Pneumococcal Conjugate Vaccine (PCV) Coverage Heterogeneities on the Changing Epidemiology of Invasive Pneumococcal Disease in Switzerland, 2005\u20132019. Microorganisms, 2021. 9(5).","DOI":"10.3390\/microorganisms9051078"},{"issue":"11","key":"14493_CR10","doi-asserted-by":"publisher","first-page":"6484","DOI":"10.1128\/AAC.03344-14","volume":"58","author":"SS Richter","year":"2014","unstructured":"Richter SS, et al. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother. 2014;58(11):6484\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"14493_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S1473-3099(20)30165-1","volume":"21","author":"N Ouldali","year":"2021","unstructured":"Ouldali N, et al. Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study. Lancet Infect Dis. 2021;21(1):137\u201347.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"14493_CR12","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1055\/s-0032-1310103","volume":"66","author":"MW Pletz","year":"2012","unstructured":"Pletz MW, et al. The burden of pneumococcal pneumonia - experience of the German competence network CAPNETZ. Pneumologie. 2012;66(8):470\u20135.","journal-title":"Pneumologie"},{"key":"14493_CR13","doi-asserted-by":"crossref","unstructured":"Shoji H et al. The Alere BinaxNOW Pneumococcal Urinary Antigen Test: Diagnostic Sensitivity for Adult Pneumococcal Pneumonia and Relationship to Specific Serotypes. J Clin Microbiol, 2018. 56(2).","DOI":"10.1128\/JCM.00787-17"},{"key":"14493_CR14","doi-asserted-by":"crossref","unstructured":"Bahrs C et al. A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany. Eur Respir J, 2022. 59(2).","DOI":"10.1183\/13993003.02432-2021"},{"issue":"10","key":"14493_CR15","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1093\/cid\/cix1066","volume":"66","author":"RG Wunderink","year":"2018","unstructured":"Wunderink RG, et al. Pneumococcal Community-Acquired Pneumonia Detected by Serotype-Specific Urinary Antigen Detection Assays. Clin Infect Dis. 2018;66(10):1504\u201310.","journal-title":"Clin Infect Dis"},{"key":"14493_CR16","volume-title":"Pathogen Identification and Outcome in Adult Patients with Community-Acquired Pneumonia in Switzerland: Findings from the Swiss CAPNETZ Cohort Study","author":"S Etienne","year":"2025","unstructured":"Etienne S, et al. Pathogen Identification and Outcome in Adult Patients with Community-Acquired Pneumonia in Switzerland: Findings from the Swiss CAPNETZ Cohort Study. Manuscript submitted for publication; 2025."},{"issue":"8","key":"14493_CR17","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1128\/CVI.00064-12","volume":"19","author":"MW Pride","year":"2012","unstructured":"Pride MW, et al. Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine. Clin Vaccine Immunol. 2012;19(8):1131\u201341.","journal-title":"Clin Vaccine Immunol"},{"issue":"9","key":"14493_CR18","doi-asserted-by":"publisher","first-page":"e430","DOI":"10.1093\/cid\/ciaa158","volume":"71","author":"WV Kalina","year":"2020","unstructured":"Kalina WV, et al. Qualification and Clinical Validation of an Immunodiagnostic Assay for Detecting 11 Additional Streptococcus pneumoniae Serotype-specific Polysaccharides in Human Urine. Clin Infect Dis. 2020;71(9):e430\u20138.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"14493_CR19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/infdis\/jiad379","volume":"229","author":"LR Grant","year":"2024","unstructured":"Grant LR, et al. Multicountry Review of Streptococcus pneumoniae Serotype Distribution Among Adults With Community-Acquired Pneumonia. J Infect Dis. 2024;229(1):282\u201393.","journal-title":"J Infect Dis"},{"key":"14493_CR20","doi-asserted-by":"crossref","unstructured":"Orsi A et al. Prevalence of Pneumococcal Serotypes in Community-Acquired Pneumonia among Older Adults in Italy: A Multicenter Cohort Study. Microorganisms, 2022. 11(1).","DOI":"10.3390\/microorganisms11010070"},{"key":"14493_CR21","doi-asserted-by":"publisher","first-page":"1086648","DOI":"10.3389\/fpubh.2023.1086648","volume":"11","author":"K Hansen","year":"2023","unstructured":"Hansen K, et al. Radiographically confirmed community-acquired pneumonia in hospitalized adults due to pneumococcal vaccine serotypes in Sweden, 2016-2018-The ECAPS study. Front Public Health. 2023;11:1086648.","journal-title":"Front Public Health"},{"key":"14493_CR22","doi-asserted-by":"crossref","unstructured":"Men\u00e9ndez R et al. Pneumococcal Serotypes Associated with Community-Acquired Pneumonia Hospitalizations in Adults in Spain, 2016\u20132020: The CAPA Study. Microorganisms, 2023. 11(11).","DOI":"10.3390\/microorganisms11112781"},{"issue":"49","key":"14493_CR23","doi-asserted-by":"publisher","first-page":"7747","DOI":"10.1016\/j.vaccine.2020.10.046","volume":"38","author":"JY Heo","year":"2020","unstructured":"Heo JY, et al. Epidemiology of community-acquired pneumonia in the era of extended serotype-covering multivalent pneumococcal conjugate vaccines. Vaccine. 2020;38(49):7747\u201355.","journal-title":"Vaccine"},{"key":"14493_CR24","doi-asserted-by":"publisher","first-page":"100812","DOI":"10.1016\/j.lanepe.2023.100812","volume":"37","author":"L Lansbury","year":"2024","unstructured":"Lansbury L, et al. Pneumococcal serotypes and risk factors in adult community-acquired pneumonia 2018-20; a multicentre UK cohort study. Lancet Reg Health Eur. 2024;37:100812.","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"14493_CR25","doi-asserted-by":"publisher","first-page":"e1154","DOI":"10.1093\/cid\/ciab1014","volume":"75","author":"D Danino","year":"2022","unstructured":"Danino D, et al. Decline in Pneumococcal Disease in Young Children During the Coronavirus Disease 2019 (COVID-19) Pandemic in Israel Associated With Suppression of Seasonal Respiratory Viruses, Despite Persistent Pneumococcal Carriage: A Prospective Cohort Study. Clin Infect Dis. 2022;75(1):e1154\u201364.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"14493_CR26","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/cid\/ciad746","volume":"78","author":"A Rybak","year":"2024","unstructured":"Rybak A, et al. Age-Specific Resurgence in Invasive Pneumococcal Disease Incidence in the COVID-19 Pandemic Era and Its Association With Respiratory Virus and Pneumococcal Carriage Dynamics: A Time-Series Analysis. Clin Infect Dis. 2024;78(4):855\u20139.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"14493_CR27","doi-asserted-by":"publisher","first-page":"e2218966","DOI":"10.1001\/jamanetworkopen.2022.18966","volume":"5","author":"R Dagan","year":"2022","unstructured":"Dagan R, Danino D, Weinberger DM. The Pneumococcus-Respiratory Virus Connection-Unexpected Lessons From the COVID-19 Pandemic. JAMA Netw Open. 2022;5(6):e2218966.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"14493_CR28","doi-asserted-by":"publisher","first-page":"e582","DOI":"10.1016\/S2589-7500(23)00108-5","volume":"5","author":"D Shaw","year":"2023","unstructured":"Shaw D, et al. Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium. Lancet Digit Health. 2023;5(9):e582\u201393.","journal-title":"Lancet Digit Health"},{"key":"14493_CR29","first-page":"2488189","volume-title":"Serotype epidemiology and case-fatality risk of invasive pneumococcal disease: a nationwide population study from Switzerland, 2012\u20132022","author":"WC Albrich","year":"2025","unstructured":"Albrich WC, et al. Serotype epidemiology and case-fatality risk of invasive pneumococcal disease: a nationwide population study from Switzerland, 2012\u20132022. Volume 14. Emerging Microbes & Infections; 2025. p. 2488189."},{"key":"14493_CR30","doi-asserted-by":"crossref","unstructured":"Camilli R et al. Invasive Pneumococcal Diseases Before and After the COVID-19 Pandemic in Italy (2018\u20132023). Microorganisms, 2025. 13(12).","DOI":"10.3390\/microorganisms13122734"},{"key":"14493_CR31","doi-asserted-by":"publisher","first-page":"1624521","DOI":"10.3389\/fcimb.2025.1624521","volume":"15","author":"S Calvo-Silveria","year":"2025","unstructured":"Calvo-Silveria S, et al. SARS-CoV-2 and Streptococcus pneumoniae colonization and disease: an observational study in adults. Front Cell Infect Microbiol. 2025;15:1624521.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"14493_CR32","doi-asserted-by":"publisher","first-page":"40146","DOI":"10.1038\/s41598-025-23819-w","volume":"15","author":"A Guerreiro-Nunes","year":"2025","unstructured":"Guerreiro-Nunes A, et al. The resilience of vaccine serotypes in adult invasive pneumococcal disease in Portugal, 2018\u20132023. Sci Rep. 2025;15(1):40146.","journal-title":"Sci Rep"},{"issue":"7","key":"14493_CR33","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/cid\/ciac100","volume":"75","author":"S Perniciaro","year":"2022","unstructured":"Perniciaro S, van der Linden M, Weinberger DM. Reemergence of Invasive Pneumococcal Disease in Germany During the Spring and Summer of 2021. Clin Infect Dis. 2022;75(7):1149\u201353.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"14493_CR34","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S1473-3099(23)00706-5","volume":"24","author":"M Bertran","year":"2024","unstructured":"Bertran M, et al. Invasive pneumococcal disease 3 years after introduction of a reduced 1\u2009+\u20091 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study. Lancet Infect Dis. 2024;24(5):546\u201356.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"14493_CR35","doi-asserted-by":"publisher","first-page":"2521845","DOI":"10.1080\/22221751.2025.2521845","volume":"14","author":"C P\u00e9rez-Garc\u00eda","year":"2025","unstructured":"P\u00e9rez-Garc\u00eda C, et al. The rise of serotype 8 is associated with lineages and mutations in the capsular operon with different potential to produce invasive pneumococcal disease. Emerg Microbes Infect. 2025;14(1):2521845.","journal-title":"Emerg Microbes Infect"},{"issue":"7","key":"14493_CR36","doi-asserted-by":"publisher","first-page":"101365","DOI":"10.1016\/j.lanmic.2026.101365","volume":"7","author":"C P\u00e9rez-Garc\u00eda","year":"2026","unstructured":"P\u00e9rez-Garc\u00eda C, et al. Upsurge of pneumococcal clade I-\u03b1\/CC180 serotype 3 and its association with a LytA mutation linked to immune evasion and disease potential: an observational and experimental study. Lancet Microbe. 2026;7(7):101365.","journal-title":"Lancet Microbe"},{"key":"14493_CR37","doi-asserted-by":"crossref","unstructured":"Lekhuleni C et al. Clonal expansion of global pneumococcal sequence cluster 3 within serotype 8 after 13-valent pneumococcal conjugate vaccine introduction, South Africa. Microb Genom, 2026. 12(6).","DOI":"10.1099\/mgen.0.001737"},{"issue":"2","key":"14493_CR38","doi-asserted-by":"publisher","first-page":"106204","DOI":"10.1016\/j.jinf.2024.106204","volume":"89","author":"C P\u00e9rez-Garc\u00eda","year":"2024","unstructured":"P\u00e9rez-Garc\u00eda C, et al. Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019\u20132023). J Infect. 2024;89(2):106204.","journal-title":"J Infect"},{"issue":"5","key":"14493_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.14745\/ccdr.v50i05a02","volume":"50","author":"A Griffith","year":"2024","unstructured":"Griffith A, et al. Invasive pneumococcal disease surveillance in Canada, 2021\u20132022. Can Commun Dis Rep. 2024;50(5):121\u201334.","journal-title":"Can Commun Dis Rep"},{"key":"14493_CR40","first-page":"2518847","volume-title":"Serotype distribution among adults with community-acquired pneumococcal pneumonia in Japan between 2019 and 2022: A multicenter observational study","author":"H Maeda","year":"2025","unstructured":"Maeda H, et al. Serotype distribution among adults with community-acquired pneumococcal pneumonia in Japan between 2019 and 2022: A multicenter observational study. Volume 21. Human Vaccines & Immunotherapeutics; 2025. p. 2518847."},{"issue":"1","key":"14493_CR41","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1128\/JCM.01573-16","volume":"55","author":"C Albrich Werner","year":"2016","unstructured":"Albrich Werner C, et al. Multiplex Urinary Antigen Detection for 13 Streptococcus pneumoniae Serotypes Improves Diagnosis of Pneumococcal Pneumonia in South African HIV-Infected Adults. J Clin Microbiol. 2016;55(1):302\u201312.","journal-title":"J Clin Microbiol"},{"issue":"18","key":"14493_CR42","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1016\/j.vaccine.2022.02.081","volume":"40","author":"JJ LeBlanc","year":"2022","unstructured":"LeBlanc JJ, et al. Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay. Vaccine. 2022;40(18):2635\u201346.","journal-title":"Vaccine"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-14493-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14493-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14493-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:13:28Z","timestamp":1790093608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-14493-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14493"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-14493-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"11 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the local ethical committees of each participating center, namely the Ethics Committee of Northwestern and Central Switzerland (Ethikkommission Nordwest- und Zentralschweiz, EKNZ), Cantonal Ethics Authority, Canton Basel-Stadt, Basel, Switzerland and the Ethics Committee of Eastern Switzerland (Ethikkommission Ostschweiz, EKOS), Eastern Switzerland Ethics Authority Canton St Gallen, St Gallen, Switzerland; BASEC ID 2009\u2009\u2212\u2009296. Written informed consent was obtained from all participants prior to study inclusion.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SE declares no conflicts of interest.WA: Honoraria: A. Vogel; Pfizer, GSK, MSD paid to my institution; Travel Support: Pfizer, Gilead, GSK paid to my institution; Advisory Boards: Aurovir; Pfizer, MSD, GSK, Sanofi, Moderna, Janssen paid to my institution.MPl: Speaker fees, advisory boards and research support from Pfizer, MSD, GSK.MPa declares no conflicts of interest.VSD declares no conflicts of interest.FE declares no conflicts of interest.GB Project funding from Pfizer and Alere GmbH\/Abbott paid to my institution.DS Honoraria: AstraZeneca, Berline-Chemie Menarini, Boehringer Ingelheim, Chiesi, CSL Behring, Insmed, GSK, Pfizer, MSD, Novartis, Sanofi, Vifor, Roche, OM-Pharma, Roche; Advisory Boards: AstraZeneca, Berline-Chemie Menarini, Boehringer Ingelheim, Chiesi, CSL Behring, Roche, GSK, Pfizer, MSD, Roche, Novartis, Sanofi, Vifor, OM-Pharma; Society Leadership: Current GOLD representative for Switzerland.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1696"}}